Healthy.io, Geisinger and Boehringer Ingelheim Study Reveals Significant Increase in Albuminuria Identification with the Addition of Smartphone Technology

Longitudinal data highlight the significant impact of adding a novel home screening test to standard lab testing, increasing opportunities for earlier identification of disease and disease management.

BOSTON, June 20, 2025 /PRNewswire/ -- Healthy.io, a leader in transforming the smartphone camera into a medical device, Geisinger, one of the nation's leading providers of value-based care, and Boehringer Ingelheim, a leading research-driven biopharmaceutical company, today announced data demonstrating the longitudinal impact of a novel chronic kidney disease (CKD) screening pilot program.

The study, supported by Boehringer Ingelheim, included 4,000 patients from Geisinger with diabetes and/or hypertension, two prominent risk factors for CKD. Patients in the pilot group received either Healthy.io's Minuteful Kidney™ smartphone-powered urine albumin-to-creatinine ratio (uACR) home test or a standard laboratory test, accompanied by patient outreach. The pilot group was compared to a 1:1 propensity-score-matched control group that received usual care (standard, routine healthcare services). Previously reported results revealed a significant 2.5-fold increase in uACR completion rates (53.1% vs. 21.2%, p<0.001) in the pilot group vs. control group.

Findings presented at the American Diabetes Association (ADA) 85^th Scientific Sessions on June 20, 2025, demonstrate that over a 270-day follow-up period, patients in the pilot group were more likely to receive a diagnosis related to CKD or proteinuria than those in the usual care arm (4.7% vs. 2.9%, p<0.001).

Based on results of the Minuteful Kidney™ test, individuals with an elevated uACR (≥30 mg/g) were more likely to complete a primary care follow-up visit (95.3% vs. 92.9%, p<0.001) or a nephrology visit (7.2% vs. 1.7%, p<0.001) compared to those with a normal uACR (< 30 mg/g). Additionally, there were a higher proportion of new ACEi/ARB prescriptions (7.5% vs. 4.4%, p=0.024) or new SGLT2i prescriptions (4.1% vs. 2.7%, p=0.054) for individuals with elevated uACR (≥30 mg/g) compared to those with uACR <30mg/g, indicating the importance of identifying albuminuria.

"Closing the uACR testing gap by reaching untested at-risk populations remains a top priority," said Geoff Martin, CEO of Healthy.io. "These study results demonstrate how smartphone-enabled testing and education can enhance CKD screening compliance, which ultimately has the potential to improve patient outcomes. We value the collaboration with Geisinger and Boehringer Ingelheim as we work to close a care gap by supporting earlier identification of CKD through screening those identified as at risk of disease."

"Detecting CKD early is crucial, as timely intervention can help mitigate the risk of disease progression and cardiovascular complications," said Brian DiDonato, Senior Vice President, Cardio-Renal-Metabolic Brands at Boehringer Ingelheim. "We are proud to support this important study of Healthy.io's Minuteful Kidney program, which presents an innovative approach to address the urgent need for enhanced CKD screening."

"uACR testing is critical for evaluating kidney health and risk of cardiovascular events such as myocardial infarction or stroke," said Alexander Chang, M.D., MS, Associate Professor from the Department of Population Health Sciences at Geisinger. "Given the increased rates of engagement, testing and follow-up care shown in this study, we are excited about the potential for the Minuteful Kidney program to drive earlier diagnosis rates and help make a direct, positive impact on patients' lives."

Limited awareness of, and access to, comprehensive screenings often contribute to poorer outcomes, emphasizing the urgent need for innovative solutions. Minuteful Kidney is the only FDA-cleared, smartphone-enabled home uACR test for CKD, allowing patients to receive clinical-grade results within minutes. As a part of the pilot program, participants in the pilot group received education via the Healthy.io engagement team. For those completing the Minuteful Kidney test, the associated app provided additional education regarding testing and supported follow-up and results sharing with healthcare providers. The pilot program demonstrated how a home testing approach can complement and help remove barriers to care.

About CKD

CKD is a national health crisis that affects more than 35 million U.S. adults, increasing their risk for cardiovascular (CV) disease, kidney failure and dialysis. Yet approximately 90% of those with CKD are unaware that they have it, as it often has no symptoms until it progresses to more advanced stages. Clinical guidelines recommend routine screenings for at-risk individuals using both estimated glomerular filtration rate (eGFR) and uACR tests; however, broad adoption of these guidelines remains low. This testing gap hinders early detection of both kidney dysfunction and CV risk, as elevated uACR is associated with an increased risk of CV events, including myocardial infarction, stroke, hospitalization for heart failure and CV death.

About Healthy.io

Healthy.io transforms the smartphone camera into a medical device to deliver healthcare at the speed of life. The company's at-home urinalysis and digitized wound care services enable providers and healthcare systems to close gaps in access and care while increasing patient satisfaction. Healthy.io is a global leader in digital health and is a recipient of the 2023 MedTech Breakthrough 'Best In-Home Testing Solution' Award and the Juniper Research's Digital Health Innovation 'Best Digital Diagnostics Solution' 2023 Award. The company has offices in Boston, London and Tel-Aviv.

About Geisinger

Geisinger is among the nation's leading providers of value-based care, serving 1.2 million people in urban and rural communities across Pennsylvania. Founded in 1915 by philanthropist Abigail Geisinger, the nonprofit system generates $10 billion in annual revenues across 126 care sites — including 10 hospital campuses — and Geisinger Health Plan, with more than half a million members in commercial and government plans. Geisinger College of Health Sciences educates more than 5,000 medical professionals annually and conducts more than 1,400 clinical research studies. With 26,000 employees, including 1,700 employed physicians, Geisinger is among Pennsylvania's largest employers with an estimated economic impact of $15 billion to the state's economy. On March 31, 2024, Geisinger became the first member of Risant Health, a new nonprofit charitable organization created to expand and accelerate value-based care across the country. Learn more at geisinger.org or follow on Facebook, Instagram, LinkedIn and X.

About Boehringer Ingelheim

Boehringer Ingelheim is a biopharmaceutical company active in both human and animal health. As one of the industry's top investors in research and development, the company focuses on developing innovative therapies that can improve and extend lives in areas of high unmet medical need. Independent since its foundation in 1885, Boehringer takes a long-term perspective, embedding sustainability along the entire value chain. Our approximately 54,500 employees serve over 130 markets to build a healthier and more sustainable tomorrow. Learn more at https://www.boehringer-ingelheim.com/us.

Media Contact - [email protected] 

Logo - https://mma.prnewswire.com/media/1856865/5366476/Healthy_io_Logo.jpg

SOURCE Healthy.io